Niagen Bioscience taps Evotec for NB4168 preclinical drug studies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
August 3, 2026 8:32 AM EDTCollaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Biosciences lead investigational candidate for rare pediatric diseases
Evotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industry
LOS ANGELES--(BUSINESS WIRE)--
Niagen Bioscience, Inc. (NASDAQ:... More
